Satoshi Yotsumoto
University of Tokyo
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Satoshi Yotsumoto.
Journal of Immunology | 2006
Yoshiyuki Adachi; Andrei L. Kindzelskii; Aaron R. Petty; Ji Biao Huang; Nobuyo Maeda; Satoshi Yotsumoto; Yasuaki Aratani; Naohito Ohno; Howard R. Petty
Macrophages and monocytes are activated by CpG DNA motifs to produce NO, which is enhanced dramatically by IFN-γ. We hypothesize that synergistic cellular responses to IFN-γ and CpG DNA are due to cross-talk between metabolic signaling pathways of leukocytes. Adherent RAW264.7 macrophages and human monocytes exhibited NAD(P)H autofluorescence oscillation periods of ∼20 s. IFN-γ increased the oscillatory amplitude, which was required for CpG DNA-mediated metabolic changes. These alterations in metabolic dynamics required the appropriate combinations of murine/human TLR9 and murine/human-specific CpG DNA. Other factors that also promoted an increase in metabolic oscillatory amplitude could substitute for IFN-γ. Because recent studies have shown that the metabolic frequency is coupled to the hexose monophosphate shunt, and the amplitude is coupled to the peroxidase cycle, we tested the hypothesis that myeloperoxidase (MPO) participates in IFN-γ priming for oxidant production. MPO inhibitors blocked cell responses to IFN-γ and CpG DNA. In the absence of IFN-γ exposure, the effects of CpG DNA could be duplicated by MPO addition to cell samples. Moreover, monocytes from MPO knockout mice were metabolically unresponsive to IFN-γ and CpG DNA. NAD(P)H frequency doubling responses due to CpG DNA were blocked by an inhibitor of the hexose monophosphate shunt. Because NAD(P)H participates in electron trafficking to NO and superoxide anions, we tested oxidant production. Although CpG DNA alone had no effect, IFN-γ plus CpG enhanced NO and reactive oxygen metabolite release compared with IFN-γ treatment alone. We suggest that amplitude and frequency modulation of cellular metabolic oscillations contribute to intracellular signaling synergy.
Journal of Immunology | 2008
Satoshi Yotsumoto; Kazuharu Saegusa; Yukihiko Aramaki
Synthetic oligodeoxynucleotides containing unmethylated CpG motifs (CpG-ODNs) function as powerful immune adjuvants by activating macrophages, dendritic cells, and B cells. However, the molecular recognition mechanism that initiates signaling in response to CpG-ODN has not fully been identified. We show in this study that peritoneal macrophages from SCID mice having mutations in the catalytic subunit of DNA-protein kinase (DNA-PKcs) were almost completely defective in the production of IL-10 and in ERK activation when treated with CpG-ODN. In contrast, IL-12 p70 production significantly increased. Furthermore, small interfering RNA (siRNA)-mediated knockdown of DNA-PKcs expression in the mouse monocyte/macrophage cell line RAW264.7 led to reduced IL-10 production and ERK activation by CpG-ODN. IL-10 and IL-12 p70 production, but not ERK activation, are blocked by chloroquine, an inhibitor of endosomal acidification. Endosomal translocation of CpG-ODN in a complex with cationic liposomes consisting of 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP) (CpG-DOTAP-liposomes) decreased IL-10 production and ERK activation, whereas the endosomal escape of CpG-ODN in a complex with cationic liposomes consisting of DOTAP and dioleyl-phosphatidylethanolamine (DOPE) (CpG-DOTAP/DOPE-liposomes) increased. In contrast, IL-12 p70 production was increased by CpG-DOTAP-liposomes and decreased by CpG-DOTAP/DOPE-liposomes. IL-10 production induced by CpG-DOTAP/DOPE-liposomes was not observed in macrophages from SCID mice. Thus, our findings suggest that DNA-PKcs in the cytoplasm play an important role in CpG-ODN-induced production of IL-10 in macrophages. In addition, DNA-PKcs-mediated production of IL-10 and IL-12 p70 can be regulated by manipulating the intracellular trafficking of CpG-ODN in macrophages.
Pharmaceutical Research | 2005
Joe Inoue; Satoshi Yotsumoto; Takatoshi Sakamoto; Seishi Tsuchiya; Yukihiko Aramaki
PurposeCpG-oligodeoxynucleotide (CpG-ODN) plays a critical role in immunity via the augmentation of Th1 and the suppression of Th2 responses. We examined here the effect of CpG-ODN on the immune response to an antigen applied to a tape-stripped skin of NC/Nga mouse, a human atopic dermatitis (AD) model, by evaluating the production of cytokines and immunoglobulin isotypes.MethodsModel antigen, ovalbumin (OVA), and CpG-ODN were applied on to the shaved skin. The penetration of OVA and CpG-ODN was evaluated using confocal laser scanning microscopy (CLSM). Secretion of cytokine from splenocytes and changes in immunoglobulin isotype levels were determined by enzyme-linked immunosorbent assay (ELISA).ResultsThrough CLSM it was revealed that the model antigen, OVA, and CpG-ODN easily penetrated the tape-stripped skin. Coadministration of CpG-ODN and OVA to the skin elicited an antigen-specific, Th1-predominant immune response and enhanced the production of IFN-γ. On the other hand, the production of a Th2-type cytokine, IL-4, was drastically suppressed. In terms of antigen-specific antibody production, the level of IgG2a regulated by IFN-γ was increased by CpG-ODN, but IgE production regulated by IL-4 was suppressed.ConclusionsAdministration of CpG-ODN with antigen through the skin may shift the immune response from a Th2- to Th1-like response. These results suggested that administration of CpG-ODN via skin is a simple strategy for patients with diseases such as AD, which is characterized by Th2-dominated inflammation.
Molecular Immunology | 2007
Kazuharu Saegusa; Satoshi Yotsumoto; Sayaka Kato; Yukihiko Aramaki
Journal of Controlled Release | 2005
Joe Inoue; Satoshi Yotsumoto; Takatoshi Sakamoto; Seishi Tsuchiya; Yukihiko Aramaki
Journal of Controlled Release | 2006
Tomomi Yoshida; Naoko Oide; Takatoshi Sakamoto; Satoshi Yotsumoto; Yoichi Negishi; Seishi Tsuchiya; Yukihiko Aramaki
Vaccine | 2007
Satoshi Yotsumoto; Terutaka Kakiuchi; Yukihiko Aramaki
Vaccine | 2004
Satoshi Yotsumoto; Yukihiko Aramaki; Terutaka Kakiuchi; Seishi Tsuchiya
Biological & Pharmaceutical Bulletin | 2002
Yukihiko Aramaki; Satoshi Yotsumoto; Hiroyuki Watanabe; Seishi Tsuchiya
Biochemical and Biophysical Research Communications | 2005
Satoshi Yotsumoto; Terutaka Kakiuchi; Yukihiko Aramaki